Next Article in Journal
Differential Induction Pattern Towards Classically Activated Macrophages in Response to an Immunomodulatory Extract from Pleurotus ostreatus Mycelium
Previous Article in Journal
Novel Cyclic Peptides from Lethal Amanita Mushrooms through a Genome-Guided Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 7
Issue 3
10.3390/jof7030205
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance

by
Karin Meinike Jørgensen
1,
Marie Helleberg
2,
Rasmus Krøger Hare
1,
Lise Nistrup Jørgensen
3 and
Maiken Cavling Arendrup
1,4,5,*
1
Unit for Mycology, Statens Serum Institut, 2300 Copenhagen, Denmark
2
Department of Infectious Diseases, Rigshospitalet, 2100 Copenhagen, Denmark
3
Department of Agroecology—Crop Health, Aarhus University-Flakkebjerg, 4200 Slagelse, Denmark
4
Department of Clinical Medicine, Copenhagen University, 2100 Copenhagen, Denmark
5
Department of Clinical Microbiology, Rigshospitalet, 2100 Copenhagen, Denmark
*
Author to whom correspondence should be addressed.
J. Fungi 2021, 7(3), 205; https://doi.org/10.3390/jof7030205
Submission received: 23 February 2021 / Revised: 9 March 2021 / Accepted: 10 March 2021 / Published: 11 March 2021
Versions Notes

Abstract

:
Azole resistance is an emerging problem in patients with aspergillosis. The role of fungicides for resistance development and occurrence is not fully elucidated. EUCAST reference MICs of 17 fungicides (11 azoles and 6 others), five azole fungicide metabolites and four medical triazoles were examined against two reference and 28 clinical isolates of A. fumigatus, A. flavus and A. terreus with (n = 12) and without (n = 16) resistance mutations. Eight/11 azole fungicides were active against wild-type A. fumigatus, A. flavus and A. terreus, including four (metconazole, prothioconazole-desthio, prochloraz and imazalil) with low MIC50 (≤2 mg/L) against all three species and epoxiconazole, propiconazole, tebuconazole and difenoconazole also against wild-type A. terreus. Mefentrifluconazole, azole metabolites and non-azole fungicides MICs were >16 mg/L against A. fumigatus although partial growth inhibition was found with mefentrifluconazole. Moreover, mefentrifluconazole and axozystrobin were active against wild-type A. terreus. Increased MICs (≥3 dilutions) were found for TR34/L98H, TR34(3)/L98H, TR46/Y121F/T289A and G432S compared to wild-type A. fumigatus for epoxiconazole, propiconazole, tebuconazole, difenoconazole, prochloraz, imazalil and metconazole (except G432S), and for prothioconazole-desthio against TR46/Y121F/T289A, specifically. Increased MICs were found in A. fumigatus harbouring G54R, M220K and M220R alterations for five, one and one azole fungicides, respectively, compared to MICs against wild-type A. fumigatus. Similarly, increased MICs wer found for A. terreus with G51A, M217I and Y491H alterations for five, six and two azole fungicides, respectively. Azole fungicides showed activity against wild-type A. fumigatus, A. terreus and A. flavus, but not against all mutant isolates, suggesting the environmental route of azole resistance may have a role for all three species.

1. Introduction

Aspergillus fumigatus, Aspergillus flavus and Aspergillus terreus exist ubiquitously in the environment. However, they are also important human pathogens causing allergic bronchopulmonary aspergillosis in patients with asthma or cystic fibrosis, chronic pulmonary aspergillosis in those with impaired lung tissue architecture and severe invasive infections in immunocompromised patients [1,2,3]. A. fumigatus is the most common cause of human Aspergillus infections globally, whereas the incidence of the other two species varies geographically. A. flavus is the second most common species in Asia but A. terreus the second most common species in Austria [1,3]. A. fumigatus is known to be abundant in decaying vegetation in fields, forests, and compost heaps while both A. terreus and A. flavus are known to be abundant in soils [4,5]. A. terreus is found in compost heaps, grassland soils and soil from potted plants from where it has been identified as a source for a hospital outbreak [6]. This species has also been reported as a contaminant of plant products like stored corn, barley and peanuts [7]. In contrast to the two others, A. flavus is considered a plant pathogen as it destroys agricultural products (corn, legumes, nuts, etc.) mainly in tropical and subtropical regions [8]. It is furthermore known for its ability to produce aflatoxin that may cause hepatitis, cancer and death.
Voriconazole and isavuconazole are licensed as first line agents for invasive Aspergillus infections, while other azoles (posaconazole and itraconazole) are alternatives [9,10,11]. Echinocandins and polyenes can also be used to treat Aspergillus infections but are less efficacious and in addition, polyenes are associated with substantial toxicity and low activity against A. terreus and A. flavus. Currently, there are no approved oral alternatives to the triazole drugs [9,10].
Azole resistance in Aspergillus is associated with substantially increased mortality [11]. Moreover, it is a global problem and the incidence of invasive Aspergillus infections caused by azole resistant strains is increasing [2,12,13]. Azole resistant infections can arise in the individual patient during long-term therapy (the patient route) or be acquired due to inhalation of resistant A. fumigatus spores present in the environment (the environmental route) [14,15,16]. In agriculture, plant pathogenic fungi have a negative effect on crops and can lead to significant economic losses, which is why fungicides are widely used [17,18]. In addition, azoles are also used as growth regulators in both arable and flower-plant production. Several classes of fungicides are used in agriculture, including succinate dehydrogenase inhibitors SDHIs, phthalimide, QoIs/strobilurins and imidazole and triazole fungicides (DMIs). The latter includes agents that have molecule characteristics very similar to the triazoles used in medicine for treatment of human infections and which have been associated with induction of a tandem repeat mechanism in A. fumigatus in vitro [14]. The role of agricultural fungicides for development of azole resistance in Aspergillus in the environment and of azole resistant Aspergillus infections in humans is debated [16,17,19].
The most common azole resistance mechanism in A. fumigatus combines point mutation(s) in the coding sequence of the cyp51A gene and an insertion of a tandem repeat in the promoter region of this gene that leads to its overexpression (TR34/L98H and TR46/Y121F/T289A), and is presumed to be of environmental origin [14,20,21,22]. Resistance can also be induced by long-term triazole treatment and is usually caused by point mutations in the cyp51A gene of both A. fumigatus and A. terreus [2,15,23]. The mechanisms causing triazole resistance in A. flavus are less well characterised. However, recent studies have identified a number of azole resistant isolates and documented Cyp51A, Cyp51B or Cyp51C target enzyme alterations [24,25,26,27,28], upregulation of target gene expression [26,29], or efflux pump upregulation [26,29,30] in the resistant isolates. Moreover, resistance has been suggested among environmental A. flavus isolates in Vietnam [31] and Argentina [25].
A feature characteristic for antimicrobial agents involved in the development or selection of resistance is to possess a higher activity against wild-type isolates than against drug resistant mutants. We compared the MICs of agricultural fungicides and medical triazoles against Aspergillus spp. isolates with wild-type susceptibility and those with resistance mutations. Whereas previous studies have focused on fungicide MICs against A. fumigatus and most on TR34/L98H, this study investigated 17 fungicides, of which 11 were agricultural azoles, and four medical mould active triazoles, and five fungicide metabolites against 12 mutant, 16 wild-type and two QC strains of A. fumigatus, A. terreus and A. flavus.

2. Materials and Methods

2.1. Isolates

Twenty-eight clinical isolates and two reference strains (A. fumigatus ATCC 204305 and A. flavus ATCC 204304) were included. Of the 28 clinical isolates, 16 were A. fumigatus sensu stricto (seven wild-type and nine with the following resistance alterations: TR34/L98H, TR34(3)/L98H, TR46/Y121F/T289A, TR120/F46Y/M172V/E427K, G432S, G54A, G54R, M220K and M220R), 10 were A. terreus (seven wild-type and three with resistance alterations: G51A, M217I, Y491H) and two were A. flavus (both wild-type). Species identification was done by classical techniques, followed by thermotolerance (incubation at 50 °C) for discriminating A. fumigatus sensu stricto from cryptic species, and by β-tubulin and calmodulin sequencing of A. terreus and A. flavus isolates [32]. The calmodulin sequencing was performed using a slightly modified method based upon Hong et al. and the following primers: ASP-CMD_F: CCGAGTACAAGGAGGCCTTC and ASP-CMD_R: TTTYTGCATCATRAGYTGGAC [33]. The underlying target gene mutation of the included mutants had been characterized by PCR amplification and sequence analysis of the cyp51A gene [16,34].

2.2. Antifungals

Seventeen agricultural fungicides (test range 32–0.03 mg/L), five azole fungicide metabolites (test range 16–0.016 mg/L) and four medical azoles were included (test range 32–0.03 mg/L). The agricultural fungicides (bixafen, boscalid, fluxapyroxad, fluopyram, folpet, azoxystrobin, prothioconazole, paclobutrazole, epoxiconazole, propiconazole, tebuconazole, difenoconazole, metconazole, prothiozonacole-desthio, prochloraz, imazalil were purchased from Sigma-Aldrich, Søborg, Denmark, whereas mefentrifluconazol was purchased from LGC Standards (Teddington, Middlesex, United Kingdom www.lgcstandards.com, accessed on 26 January 2021). The metabolites included: 1,2,3-triazole (Sigma-Aldrich, Søborg, Denmark), 1,2,4-triazole and triazole sulfonamide (Toronto Research Chemicals, Toronto, Canada), and triazole alanine and triazole acetate (HPC Standards GmbH, Borsdorf, Germany). The medical antifungal agents used were itraconazole, voriconazole, isavuconazole and posaconazole (all from Sigma-Aldrich, Søborg, Denmark, except isavuconazole, which derived from Basilea).

2.3. Susceptibility Testing

The isolates were tested according to the EUCAST E.Def 9.3.2 microdilution method, with standard filtration (11-nm filter) of the inoculum [35]. Susceptibility testing was performed once, but repeated if growth curves were abnormal (bumpy) or growth was insufficient. Stock solutions of the antifungals were prepared at 5000 mg/L in dimethyl sulfoxide (Sigma-Aldrich, Søborg, Denmark). Cell culture-treated microtitre polystyrene plates (Nunc microwell 96-well microplates, catalog no. 167008; Thermo Fisher Scientific) were used throughout. At 48 h, the MIC was determined visually as the concentrations that produced a complete inhibition of growth. For mefentriazole specifically the plates were also read spectrophometrically and spectrophotometric MICs (spec-MICs) were determined using 50, 60, 70, 80 and 90% inhibition of the optical density as endpoints (Table S1). As breakpoints do not exist for fungicides against Aspergillus, we regarded isolates resistant when the MIC was >16 mg/L.

2.4. Data Analysis

The MIC50, defined as the minimum concentration at which 50% of the isolates were inhibited was determined for the wild-type isolates of A. fumigatus and A. terreus. The relative efficacy of fungicides, fungicide metabolites and medical triazoles against wild-type versus mutant isolates was determined as the number of twofold dilution step differences in concentration that caused complete inhibition of growth of Aspergillus by determining the log2(mutant MIC) – log2(wild-type MIC50 ). For these calculations, MICs of >32 mg/L were translated to 64 mg/L. A log2 MIC difference of ≥3 (for example for MICs 8 vs. 1 mg/L) was considered significant.

3. Results

Seventeen agricultural fungicides, five fungicide metabolites and four medical triazoles, were tested against wild-type and mutant isolates of A. fumigatus, A. terreus and A. flavus. The susceptibility patterns of the medical azoles were in agreement with the well-known patterns confirming a reliable performance of the susceptibility testing and correct identification of species and underlying resistance mutations (Table 1) [2,16].

3.1. Fungicide Activity against Wild-Type Aspergillus Isolates

Nine azole fungicides displayed in vitro activity against wild-type A. fumigatus using a complete growth inhibition endpoint. Of these, four were highly active with MIC50 values of 0.06–0.5 mg/L (metconazole, prothioconazole-desthio, prochloraz and imazalil), and five were moderately active with MIC50 values of 2–16 mg/L (paclobutrazole, epoxiconazole, propiconazole, tebuconazole, and difenoconazole) (Table 1). Ten azole fungicides were in vitro active against A. terreus. These included five highly active difenoconazole, metconazole, prothioconazole-desthio, prochloraz and imazalil with MIC50 ≤ 1 mg/L and five that displayed weaker activity with MIC50 2–8 mg/L (mefentrifluconazole, paclobutrazole, epoxiconazole, propiconazole, tebuconazole). Finally, nine of these were also active against wild-type isolates of A. flavus: metconazole, prothioconazole-desthio, prochloraz and imazalil with MIC50 values of 0.5–2 mg/L, and paclobutrazole, epoxiconazole, propiconazole, tebuconazole, and difenoconazole with MIC50 values of 8–16 mg/L. No activity was observed for the fungicide metabolites or the non-azole fungicides against wild-type isolates of the three Aspergillus species, with the exception azoxystrobin against A. terreus (MIC50 of 0.58 mg/L, Table 1).

3.2. Activity of Azole Fungicides against cyp51A Mutant Aspergillus

The four mutant A. fumigatus with tandem repeats in the promotor region of the cyp51A gene were resistant (MIC > 16 mg/L) to prothioconazole, mefentrifluconazole, paclobutrazole, epoxiconazole, propiconazole, tebuconazole and difenoconazole. Metconazole, prothioconazole-desthio, prochloraz and imazalil were active against TR34/L98H, TR34(3)/L98H, and TR120/F46Y/M172V/E427K (MICs of 0.125–8 mg/L) whereas metconazole (MIC 16 mg/L) and prothioconazole-desthio (1 mg/L) were the only agents with in vitro activity against TR46/Y121F/T289A. Among the isolates with single point mutations in the target gene, the susceptibility of the G432S mutant resembled that of the TR34/L98H, whereas the remaining mutants of A. fumigatus and A. terreus with single point mutations were more susceptible than the isolate harbouring the TR34/L98H to one or more of the following fungicides: epoxiconazole, propiconazole, tebuconazole, difenoconazole (Table 1).

3.3. The Relative Susceptibility of wt and Mutant Isolates

The relative susceptibility of wt and mutant isolates to azole fungicides was determined as the difference between log2 transformed MICs for mutants and wt isolates (Table 2). A log2 MIC difference of three or greater was found for the TR34/L98H, TR34(3)/L98H, TR46/Y121F/T289A and G432S mutants compared to wild-type A. fumigatus with epoxiconazole, propiconazole, tebuconazole, difenoconazole, metconazole (except G432S), prochloraz and imazalil. In addition, a log2 MIC difference of four was found for prothioconazole-desthio against TR46/Y121F/T289A but not TR34 tandem repeat mutants. The azole fungicides that displayed the greatest MIC elevation against the TR34/L98H and TR34(3)/L98H were difenoconazole and imazalil (four to five two-fold dilutions), whereas tebuconazole, difenoconazole, metconazole, prothioconazole-desthio, prochloraz and imazalil displayed the greatest MIC elevation against TR46/Y121F/T289A (four to seven two-fold dilutions).
Among the remaining mutants (isolated from patients with medical azole exposure), MIC elevations of three or more two-fold dilutions to several azole fungicides were found in A. fumigatus strains harbouring the TR120/F46Y/M172V/E427K (particularly difenoconazole) and G54R (particularly metconazole, prothioconazole-desthio and prochloraz) alterations, but not in isolates harbouring either the G54A, M220K (except epoxiconazole) or M220R (except prochloraz) alterations (Table 2). On the contrary, in A. terreus, MIC elevations of three or more dilutions were observed in isolates harbouring the G51A, and M217I alterations for epoxiconazole, propiconazole, tebuconazole, difenoconazole and mefentrifluconazole, and for the M217I specifically also for prochloraz. Finally, the susceptibility of the Y491H mutant A. terreus was less affected as a three-dilution elevation of MICs was only observed for two compounds (mefentrifluconazole and prochloraz).

3.4. Mefentriflucon Azole Displayed an Atypical Inhibition Pattern against Aspergillus

Complete growth inhibition was not achieved for mefentrifluconazole against neither wild-type nor mutant isolates of A. fumigatus and A. flavus even at the highest concentration tested (32 mg/L). However, partial inhibition was consistently observed for all three Aspergillus species at the higher concentrations and therefore endpoints were determined based on a range of 50% to 90% growth inhibition endpoints (Table S1). A ≥3 log2 MIC elevation (MIC ≥ 16 mg/L) compared to the wild-type (MIC50 4 mg/L) was observed for A. fumigatus mutants harbouring TR34/L98H, TR34(3)/L98H, TR46/Y121F/T289A, TR120/F46Y/M172V/E427K and the M220R as well as for all three mutants of A. terreus (MICs 16->16 mg/L) compared to the wild-type (MIC50 2 mg/L) when the spectrophotometric 50% inhibition endpoint was adopted.

3.5. Activity of Non-Azole Fungicides and Azole Fungicide Metabolites against Aspergillus

Whereas the non-azole fungicides were inactive against wild-type A. fumigatus and A. flavus, the SDHI fungicides bixafen, boscalid and fluxapyroxad (anilid) displayed activity against the A. fumigatus mutants TR120/F46Y/M172V/E427K, G432S and G54A (MICs 1–4 mg/L) (Table 1). Similarly, activity was observed of the SDHI fungicide fluopyram (a benzamide) against the TR120/F46Y/M172V/E427K and G54A A. fumigatus mutants (MICs 4 mg/L) and of azoxystrobin (QoI /strobilurin) against the TR120/F46Y/M172V/E427K mutant (MIC 8 mg/L). In contrast, only azoxystrobin displayed activity against wild-type isolates and the Y491H mutant of A. terreus, but not against the G54A and M217I mutants of A. terreus.

4. Discussion

The circumstantial evidence suggesting that TR34/L98H, TR46/Y121F/T289A and the less common TR46(3)/Y121F/T289A and TR53 azole resistance mechanisms in A. fumigatus originate from the environment is compelling [17,20,36,37]. This is in part because susceptible isogenic counterparts have never been isolated in humans and because resistant infections are diagnosed in azole naïve patients. However, it has become clear over the recent years that isolates with tandem repeats can also occasionally arise in humans during medical therapy. Thus, an isolate with a 120 base pair tandem repeat in the promotor region (TR120/F46Y/M172V/E427K) was recently demonstrated to have emerged in a patient during azole therapy [38]. It is also well documented that the list of point mutations in the cyp51A target gene that can arise during medical azole therapy and cause resistance is long and growing [17]. The single amino acid alterations M220K and M220R have only been found in azole-exposed patients. Nevertheless, it has become clear that several point mutations causing azole resistance can also be found in environmental isolates. For example, A. fumigatus isolates harbouring single point target gene mutations have been found in the environment including G54A in Germany [39], G54E in Italy, India, Romania, Tanzania, and Argentina [40,41,42,43], G54R in Switzerland and Thailand [44,45], M220I in Germany [39], P216L and H285Y in France [46,47], and G448S in China [48]. Moreover, clinical A. flavus isolates harbouring point mutations conferring Cyp51A P214L (itraconazole and posaconazole resistant) or Cyp51C H349R (pan human azole resistant) alterations displayed cross resistance to imazalil, prochloraz, metconazole, tebuconazole, epoxiconazole, and bromuconazole [28]. Besides an environmental itraconazole and voriconazole resistant A. flavus isolate from Argentina was found to harbour Cyp51C S361W and N423D alterations [25]. On this background, it is plausible that selection of azole resistance in the environment can take place not only in A. fumigatus but also in other clinically relevant Aspergillus species and that the underlying mechanisms are not limited to those consisting of the combination of tandem repeats and target gene mutations. Therefore, in this study we investigated the differential activity of fungicides (and azole fungicide metabolites) against wild-type and various mutant isolates of A. fumigatus, A. flavus and A. terreus.
Epoxiconazole, propiconazole, tebuconazole and difenoconazole have previously been associated with selection of the TR34/L98H resistance mechanism in A. fumigatus [14]. We confirmed activity of these agents against wild-type A. fumigatus but also against wild-type A. terreus and A. flavus suggesting they may also pose a selection pressure for resistance in these species. An MIC elevation comparable to that seen in TR34/L98H was observed in A. fumigatus harbouring TR46/Y121F/T289A, TR120/F46Y/M172V/E427K and G432S and the three A. terreus isolates with G51A, M217I and Y491H, suggesting that acquisition of all these alterations may be an advantage in an environment where these four agents are applied. This may also be the case in A. fumigatus for the G54R and M220K alterations for tebuconazole and epoxiconazole, respectively.
Metconazole, prothioconazole-desthio, prochloraz and imazalil were more active against wild-type A. fumigatus, A. terreus and A. flavus than the other azole fungicides on a mg/L basis. The strongest reduction in susceptibility to these four agents was conferred by the TR46/Y121F/T289A and G54R alteration in A. fumigatus. Of note, TR46/Y121F/T289A and G54R were the only mutants with acquired resistance to prothioconazole-desthio suggesting this fungicide is not implicated in selection of TR34/L98H or any of the included point mutations in A. fumigatus. In contrast, metconazole, prochloraz and imazalil activity was reduced in TR34/L98H and one or both of the latter two also in G432S, TR120/F46Y/M172V/E427K and M220R A. fumigatus isolates.
The non-azole fungicides were in general not active against Aspergillus wild-type isolates with the exception of azoxystrobin against A. terreus. These agents belong to drug classes that are not used in human medicine and which, when used for plant protection are often used in combination with azole fungicides. The SDHIs bixafen and fluxapyroxad are frequently used outside Denmark in combination with azoles (prothioconazole, epoxiconazole and as of 2021 also mefentrifluconazole). Similarly, fluopyram with prothioconazole and boscalid with epoxiconazole are frequently used combinations in Denmark. Although inactive against the included wild-type A. fumigatus isolates, activity was observed against some of the mutant isolates of A. fumigatus. This was true for bixafen, boscalid and fluxapyroxad against TR120/F46Y/M172V/E427K (selected via the patient route), G432S (also found in an azole naïve patient), and G54A (selected via the patient route and occasionally found in the environment), and was also true for fluopyram against TR120/F46Y/M172V/E427K and G54A. In contrast, none of them were active against G54R, which is found in the environment in Switzerland and Thailand, nor against the two most common environmental mutants, TR34/L98H and TR46/Y121F/T289A. It remains to be understood if the use of these non-azole fungicides in combination with azoles may help prevent selection of for example G54A and G432S mutants in the environment. On the other hand, a recent study from the UK showed that in addition to azole resistance, several lineages of A. fumigatus carrying TR-based Cyp51A variants have also acquired resistance to three other groups of fungicides, namely methyl benzimidazole carbamate, strobiluriner (QoI) and (SDHIs) through target-site alterations in the corresponding fungicide target proteins [19]. This illustrates the capacity of A. fumigatus to evade a selection pressure in the environment and may explain the high level of resistance against these non-azole fungicides in the wild-type isolates included in this study.
Prothioconazole, mefentrifluconazole and the five azole metabolites did not display fungicidal activity against A. fumigatus or A. flavus, suggesting that these agents are improbable drives of resistance in these species. Once applied to the target, prothioconazole is, however, rapidly metabolised to prothioconazole-destio, which is present in the upper layers of soil, a more potent selector for resistance in plant pathogens and active against A. fumigatus [49,50]. Another potential caveat was that a partial inhibition pattern was observed for mefentrifluconazole against A. fumigatus and A. terreus that was not observed for the other agents and not observed against TR34/L98H, TR120/F46Y/M172V/E427K, G54A, M220K and M220R nor against A. terreus harbouring G51A, M217I and Y491H. Therefore, further studies are warranted before confirming that this partial inhibition of mefentrifluconazole may not present a relevant selection pressure on Aspergillus in the environment.

5. Conclusions

In conclusion, our study shows that prothioconazole, paclobutrazole, potentially mefentrifluconazole and the five well-known azole metabolites showed no or low activity against A. fumigatus, A. terreus and A. flavus, and thus are unlikely drivers of resistance. However, differential activity was observed for the other azole fungicides, including the prothioconazole-destio metabolite of prothioconazole, which may suggest that given the “right” circumstances, these may pose a selection pressure on all three Aspergillus species. Moreover, not only the recognised TR34/L98H and TR46/Y121F/T289A environmental mutations, but also seven of the eight point mutations in A. fumigatus and A. terreus increased the MIC to at least one fungicide by at least three two-fold dilutions, suggesting these mutations confer an advantage for the fungus to escape both environmental fungicides and medical azoles. Most azoles are rather persistent in soils when measured as DT50 (= time for disappearance of half the chemical). Half-lives are variable but range from months to years (Table 3). Field applications with azoles will expectedly impact the concentration in the upper soil layers where A. fumigatus can be expected to be present and in this way azole-fungicides may act as a potent selector for resistance. Despite common cases of azole resistance in plant pathogens attacking field crops [51], a recent investigation only found a few cases with resistant A. fumigatus in farmer fields treated with azoles, suggesting that other uses may be more important for resistance selection [19].
Taken together, these and our findings illustrate that studies focussing on identifying local practices in each country that are important for the selection of azole resistance in Aspergillus are of utmost importance. This is in order to identify potentially safe and beneficial practices for agricultural yield from the uses of fungicides that drive resistance in human pathogens.

Supplementary Materials

The following are available online at https://www.mdpi.com/2309-608X/7/3/205/s1, Table S1: Mefentrifluconazole MIC (mg/L) with complete visual and partial spectrophotometric inhibition endpoints.

Author Contributions

Conceptualisation, L.N.J. and M.C.A.; Data curation, K.M.J.; Formal analysis, K.M.J., M.H. and M.C.A.; Funding acquisition, M.C.A.; Investigation, K.M.J. and M.C.A.; Methodology, K.M.J., R.K.H. and M.C.A.; Project administration, K.M.J. and M.C.A.; Resources, M.C.A.; Supervision, M.C.A.; Visualisation, M.C.A.; Writing-original draft, M.H. and M.C.A.; Writing—review and editing, L.N.J. All authors have read and agreed to the published version of the manuscript.

Funding

The study was supported by the Ministry of Environment and Food of Denmark. M.H. received support from the Danish National Research Foundation, grant #126.

Data Availability Statement

Not applicable.

Acknowledgments

The authors wish to thank Birgit Brandt and Désiré Mageme Nahimana for excellent technical assistance.

Conflicts of Interest

“The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results”. Outside this work, the authors have the following potential conflicts to declare: M.C.A. has, over the past 5 years, received research grants (paid to the institution) or speaker honoraria (personal fee) from Amplyx, Astellas, Basilea, Cidara, F2G, Gilead, MSD, Novartis, Pfizer, and T2Biosystems. She is the current chairman of the EUCAST-AFST and has previously served on advisory boards for MSD (until 2014) and Pfizer (until 2012). M.H. has, over the past 5 years, received speaker honoraria from GSK, CLS Behring and Gilead and has served on advisory boards for GSK. Gilead and GSK have funded her participation in international scientific meetings and conferences. R.K.H. has over the past 5 years received travel grant and an unrestricted research grant from Gilead. L.N.J. has over the years received research grants (paid to the institution), speaker honoraria (personal fee) and funding for participation in workshops/meetings from BASF, Bayer, Syngenta, Corteva, Adama, Novozymes, UPL, ECOstyle, DLG, Nordic Seed, Sejet, KWS and Globachem K.M.J. has over the past 5 years received travel grants from F2G and Amplyx and a meeting grant from MSD.

References

  1. Lass-Flörl, C.; Mayr, A.; Aigner, M.; Lackner, M.; Orth-Höller, D. A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol, Austria. Infection 2018, 46, 701–704. [Google Scholar] [CrossRef] [Green Version]
  2. Risum, M.; Hare, R.K.; Gertsen, J.B.; Kristensen, L.; Johansen, H.K.; Helweg-Larsen, J.; Abou-Chakra, N.; Pressler, T.; Skov, M.; Jensen-Fangel, S.; et al. Azole-Resistant Aspergillus fumigatus Among Danish Cystic Fibrosis Patients: Increasing Prevalence and Dominance of TR34/L98H. Front. Microbiol. 2020, 11, 1850. [Google Scholar] [CrossRef] [PubMed]
  3. Cho, S.Y.; Lee, D.G.; Choi, J.K.; Lee, H.J.; Kim, S.H.; Park, S.H.; Choi, S.M.; Choi, J.H.; Yoo, J.H.; Park, Y.J.; et al. Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: Comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species. Medicine 2017, 96, e8841. [Google Scholar] [CrossRef]
  4. Klich, M.A. Aspergillus flavus: The major producer of aflatoxin. Mol. Plant Pathol. 2007, 8, 713–722. [Google Scholar] [CrossRef]
  5. Samson, R.A.; Peterson, S.W.; Frisvad, J.C.; Varga, J. New species in Aspergillus section Terrei. Stud. Mycol. 2011, 69, 39–55. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Lass-Flörl, C.; Rath, P.-M.; Niederwieser, D.; Kofler, G.; Würzner, R.; Krezy, A.; Dierich, M.P. Aspergillus terreus infections in haematological malignancies: Molecular epidemiology suggests association with in-hospital plants. J. Hosp. Infect. 2000, 46, 31–35. [Google Scholar] [CrossRef] [PubMed]
  7. Kozakiewicz, Z. Aspergillus species on stored products. Mycol. Pap. 1989, 161, 1–188. [Google Scholar]
  8. Leger, R.J.S.; Screen, S.E.; Shams-Pirzadeh, B. Lack of Host Specialization inAspergillus flavus. Appl. Environ. Microbiol. 2000, 66, 320–324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Ullmann, A.J.; Aguado, J.M.; Arikan-Akdagli, S.; Denning, D.W.; Groll, A.H.; Lagrou, K.; Lass-Flörl, C.; Lewis, R.E.; Munoz, P.; Verweij, P.E.; et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 2018, 24 (Suppl. 1), e1–e38. [Google Scholar] [CrossRef] [Green Version]
  10. Denning, D.W.D.; Cadranel, J.; Beigelman-Aubry, C.; Ader, F.; Chakrabarti, A.; Blot, S.; Ullmann, A.J.; Dimopoulos, G.; Lange, C.; Ullman, A.; et al. Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management. Eur. Respir. J. 2016, 47, 45–68. [Google Scholar] [CrossRef] [PubMed]
  11. Wilson, D.T.; Dimondi, V.P.; Johnson, S.W.; Jones, T.M.; Drew, R.H. Role of isavuconazole in the treatment of invasive fungal infections. Ther. Clin. Risk Manag. 2016, 12, 1197–1206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Lestrade, P.P.; Bentvelsen, R.G.; Schauwvlieghe, A.F.A.D.; Schalekamp, S.; van der Velden, W.J.F.M.; Kuiper, E.J.; van Paassen, J.; van der Hoven, B.; van der Lee, H.A.; Melchers, W.J.G.; et al. Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. Clin. Infect. Dis. 2019, 68, 1463–1471. [Google Scholar] [CrossRef] [Green Version]
  13. Lestrade, P.P.A.; Meis, J.F.; Melchers, W.J.G.; Verweij, P.E. Triazole resistance in Aspergillus fumigatus: Recent insights and challenges for patient management. Clin. Microbiol. Infect. 2019, 25, 799–806. [Google Scholar] [CrossRef] [PubMed]
  14. Meis, J.F.; Chowdhary, A.; Rhodes, J.L.; Fisher, M.C.; Verweij, P.E. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos. Trans. R. Soc. B Biol. Sci. 2016, 371, 20150460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Snelders, E.; Camps, S.M.T.; Karawajczyk, A.; Schaftenaar, G.; Kema, G.H.J.; van der Lee, H.A.; Klaassen, C.H.; Melchers, W.J.G.; Verweij, P.E. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE 2012, 7, e31801. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Mortensen, K.L.; Jensen, R.H.; Johansen, H.K.; Skov, M.; Pressler, T.; Howard, S.J.; Leatherbarrow, H.; Mellado, E.; Arendrup, M.C. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: A laboratory-based study with focus on Aspergillus fumigatus azole resistance. J. Clin. Microbiol. 2011, 49, 2243–2251. [Google Scholar] [CrossRef] [Green Version]
  17. Buil, J.B.; Hare, R.K.; Zwaan, B.J.; Arendrup, M.C.; Melchers, W.J.G.; Verweij, P.E. The fading boundaries between patient and environmental routes of triazole resistance selection in Aspergillus fumigatus. PLoS Pathog. 2019, 15, e1007858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Stensvold, C.R.; Jørgensen, L.N.; Arendrup, M.C. Azole-Resistant Invasive Aspergillosis: Relationship to Agriculture. Curr. Fungal Infect. Rep. 2012, 6, 178–191. [Google Scholar] [CrossRef]
  19. Gisi, U. Assessment of selection and resistance risk for demethylation inhibitor fungicides in Aspergillus fumigatus in agriculture and medicine: A critical review. Pest Manag. Sci. 2014, 70, 352–364. [Google Scholar] [CrossRef] [PubMed]
  20. Fraaije, B.; Atkins, S.; Hanley, S.; Macdonald, A.; Lucas, J. The Multi-Fungicide Resistance Status of Aspergillus fumigatus Populations in Arable Soils and the Wider European Environment. Front. Microbiol. 2020, 11, 599233. [Google Scholar] [CrossRef]
  21. Vermeulen, E.; Lagrou, K.; Verweij, P.E. Azole resistance in Aspergillus fumigatus: A growing public health concern. Curr. Opin. Infect. Dis. 2013, 26, 493–500. [Google Scholar] [CrossRef]
  22. Zhang, J.; Lopez Jimenez, L.; Snelders, E.; Debets, A.J.M.; Rietveld, A.G.; Zwaan, B.J.; Verweij, P.E.; Schoustra, S.E. Dynamics of Aspergillus fumigatus in azole-fungicide-containing plant waste, the Netherlands, 2016–2017. Appl. Environ. Microbiol. 2021, 87, e02295-20. [Google Scholar] [CrossRef] [PubMed]
  23. Verweij, P.E.; Lucas, J.A.; Arendrup, M.C.; Bowyer, P.; Brinkmann, A.J.F.; Denning, D.W.; Dyer, P.S.; Fisher, M.C.; Geenen, P.L.; Gisi, U.; et al. The one health problem of azole resistance in Aspergillus fumigatus: Current insights and future research agenda. Fungal Biol. Rev. 2020. [Google Scholar] [CrossRef]
  24. Bueid, A.; Howard, S.J.; Moore, C.B.; Richardson, M.D.; Harrison, E.; Bowyer, P.; Denning, D.W. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 2010, 65, 2116–2118. [Google Scholar] [CrossRef] [PubMed]
  25. Rivero-Menendez, O.; Soto-Debran, J.C.; Medina, N.; Lucio, J.; Mellado, E.; Alastruey-Izquierdo, A. Molecular identification, antifungal susceptibility testing, and mechanisms of azole resistance in Aspergillus species received within a surveillance program on antifungal resistance in Spain. Antimicrob. Agents Chemother. 2019, 63, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Hermida-Alava, K.; Brito Devoto, T.; Sautua, F.; Gordó, M.; Scandiani, M.; Formento, N.; Luque, A.; Carmona, M.; Cuestas, M.L. Antifungal susceptibility profile and molecular identification of Cyp51C mutations in clinical and environmental isolates of Aspergillus flavus from Argentina. Mycoses 2021, 64, 95–101. [Google Scholar] [CrossRef]
  27. Sharma, C.; Kumar, R.; Kumar, N.; Masih, A.; Gupta, D.; Chowdhary, A. Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India. Antimicrob. Agents Chemother. 2018, 62, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Paul, R.A.; Rudramurthy, S.M.; Meis, J.F.; Mouton, J.W.; Chakrabarti, A. A Novel Y319H Substitution in CYP51C Associated with Azole Resistance in Aspergillus flavus. Antimicrob. Agents Chemother. 2015, 59, 6615–6619. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Lucio, J.; Gonzalez-Jimenez, I.; Rivero-Menendez, O.; Alastruey-Izquierdo, A.; Pelaez, T.; Alcazar-Fuoli, L.; Mellado, E. Point Mutations in the 14-α Sterol Demethylase Cyp51A or Cyp51C Could Contribute to Azole Resistance in Aspergillus flavus. Genes 2020, 11, 1217. [Google Scholar] [CrossRef]
  30. Paul, R.A.; Rudramurthy, S.M.; Dhaliwal, M.; Singh, P.; Ghosh, A.K.; Kaur, H.; Varma, S.; Agarwal, R.; Chakrabarti, A. Voriconazole resistance in clinical and environmental isolates of Aspergillus flavus—frequency and investigation into the role of multidrug efflux pumps. Antimicrob. Agents Chemother. 2018, 62, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Ukai, Y.; Kuroiwa, M.; Kurihara, N.; Naruse, H.; Homma, T.; Maki, H.; Naito, A. Contributions of yap1 Mutation and Subsequent atrF Upregulation to Voriconazole Resistance in Aspergillus flavus. Antimicrob. Agents Chemother. 2018, 62, 1–11. [Google Scholar] [CrossRef] [Green Version]
  32. Duong, T.M.N.; Nguyen, P.T.; Van Le, T.; Nguyen, H.L.P.; Nguyen, B.N.T.; Nguyen, B.P.T.; Nguyen, T.A.; Chen, S.C.A.; Barrs, V.R.; Halliday, C.L.; et al. Drug-resistant aspergillus flavus is highly prevalent in the environment of Vietnam: A new challenge for the management of aspergillosis? J. Fungi 2020, 6, 296. [Google Scholar] [CrossRef]
  33. Hong, S.-B.; Go, S.-J.; Shin, H.-D.; Frisvad, J.C.; Samson, R.A. Polyphasic taxonomy of Aspergillus fumigatus and related species. Mycologia 2005, 97, 1316–1329. [Google Scholar] [CrossRef]
  34. Arendrup, M.C.; Jensen, R.H.; Grif, K.; Skov, M.; Pressler, T.; Johansen, H.K.; Lass-Flörl, C. In vivo emergence of aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I Alteration. J. Infect. Dis. 2012, 206, 981–985. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Arendrup, M.C.; Meletiadis, J.; Mouton, J.W.; Guinea, J.; Cuenca-Estrella, M.; Lagrou, K.; Howard, S.J. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin. Microbiol. Infect. 2016, 22, 571.e1-4. [Google Scholar] [CrossRef] [Green Version]
  36. Zhang, J.; Snelders, E.; Zwaan, B.J.; Schoustra, S.E.; Meis, J.F.; van Dijk, K.; Hagen, F.; van der Beek, M.T.; Kampinga, G.A.; Zoll, J.; et al. A Novel Environmental Azole Resistance Mutation in Aspergillus fumigatus and a Possible Role of Sexual Reproduction in Its Emergence. MBio 2017, 8, e00791-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Alvarez-Moreno, C.; Lavergne, R.-A.; Hagen, F.; Morio, F.; Meis, J.F.; Le Pape, P. Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia. Sci. Rep. 2017, 7, 45631. [Google Scholar] [CrossRef] [PubMed]
  38. Hare, R.K.; Gertsen, J.B.; Astvad, K.M.T.; Degn, K.B.; Løkke, A.; Stegger, M.; Andersen, P.S.; Kristensen, L.; Arendrup, M.C. In Vivo Selection of a Unique Tandem Repeat Mediated Azole Resistance Mechanism (TR120) in Aspergillus fumigatus cyp51A, Denmark. Emerg. Infect. Dis. 2019, 25, 577–580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Bader, O.; Tünnermann, J.; Dudakova, A.; Tangwattanachuleeporn, M.; Weig, M.; Groß, U.; Hoberg, N.; Geibel, S.; Vogel, E.; Büntzel, J.; et al. Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob. Agents Chemother. 2015, 59, 4356–4359. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Prigitano, A.; Esposto, M.C.; Romanò, L.; Auxilia, F.; Tortorano, A.M. Azole-resistant Aspergillus fumigatus in the Italian environment. J. Glob. Antimicrob. Resist. 2019, 16, 220–224. [Google Scholar] [CrossRef] [PubMed]
  41. Sharma, C.; Nelson-Sathi, S.; Singh, A.; Radhakrishna Pillai, M.; Chowdhary, A. Genomic perspective of triazole resistance in clinical and environmental Aspergillus fumigatus isolates without cyp51A mutations. Fungal Genet. Biol. 2019, 132, 103265. [Google Scholar] [CrossRef]
  42. Sharma, C.; Hagen, F.; Moroti, R.; Meis, J.F.; Chowdhary, A. Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired? J. Glob. Antimicrob. Resist. 2015, 3, 69–74. [Google Scholar] [CrossRef] [PubMed]
  43. Leonardelli, F.; Theill, L.; Nardin, M.E.; Macedo, D.; Dudiuk, C.; Mendez, E.; Gamarra, S.; Garcia-Effron, G. First itraconazole resistant Aspergillus fumigatus clinical isolate harbouring a G54E substitution in Cyp51Ap in South America. Rev. Iberoam. Micol. 2017, 34, 46–48. [Google Scholar] [CrossRef] [PubMed]
  44. Riat, A.; Plojoux, J.; Gindro, K.; Schrenzel, J.; Sanglard, D. Azole Resistance of Environmental and Clinical Aspergillus fumigatus Isolates from Switzerland. Antimicrob. Agents Chemother. 2018, 62, e02088-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Tangwattanachuleeporn, M.; Minarin, N.; Saichan, S.; Sermsri, P.; Mitkornburee, R.; Groß, U.; Chindamporn, A.; Bader, O. Prevalence of azole-resistant Aspergillus fumigatus in the environment of Thailand. Med. Mycol. 2017, 55, 429–435. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Jeanvoine, A.; Rocchi, S.; Reboux, G.; Crini, N.; Crini, G.; Millon, L. Azole-resistant Aspergillus fumigatus in sawmills of Eastern France. J. Appl. Microbiol. 2017, 123, 172–184. [Google Scholar] [CrossRef]
  47. Dauchy, C.; Bautin, N.; Nseir, S.; Reboux, G.; Wintjens, R.; Le Rouzic, O.; Sendid, B.; Viscogliosi, E.; Le Pape, P.; Arendrup, M.C.; et al. Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes. Indoor Air 2018, 28, 298–306. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Cao, D.; Wu, R.; Dong, S.; Wang, F.; Ju, C.; Yu, S.; Xu, S.; Fang, H.; Yu, Y. Five-Year Survey (2014 to 2018) of Azole Resistance in Environmental Aspergillus fumigatus Isolates from China. Antimicrob. Agents Chemother. 2020, 64, 1–6. [Google Scholar] [CrossRef] [PubMed]
  49. Parker, J.E.; Warrilow, A.G.S.; Cools, H.J.; Martel, C.M.; Nes, W.D.; Fraaije, B.A.; Lucas, J.A.; Kelly, D.E.; Kelly, S.L. Mechanism of binding of prothioconazole to Mycosphaerella graminicola CYP51 differs from that of other azole antifungals. Appl. Environ. Microbiol. 2011, 77, 1460–1465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. EFSA. Conclusion on the Peer Review of Prothioconazole; EFSA Scientific Report; EFSA: Parma, Italy, 2007; Volume 106, pp. 1–98. [Google Scholar]
  51. Lucas, J.A.; Hawkins, N.J.; Fraaije, B.A. The Evolution of Fungicide Resistance. In Advances in Applied Microbiology; Sariaslani, S., Gadd, G.M., Eds.; Elsevier: Amsterdam, The Netherlands, 2015; Volume 90, pp. 29–92. [Google Scholar]
Table
Table 1. In vitro activity (EUCAST MICs (mg/L) with visual complete inhibition endpoint) of 11 azole fungicides, four medical triazoles, five azole fungicide metabolites and six non azole fungicides against wild-type and cyp51A mutant isolates of three Aspergillus species.
Table 1. In vitro activity (EUCAST MICs (mg/L) with visual complete inhibition endpoint) of 11 azole fungicides, four medical triazoles, five azole fungicide metabolites and six non azole fungicides against wild-type and cyp51A mutant isolates of three Aspergillus species.
Fungicide Class and CompoundA. fumigatusA. terreusA. flavus
ATCC 204305 *Wild-Type
(n = 7) a		TR34/
L98H 		TR34(3)/L98H TR46/Y121F/T289ATR120/F46Y/
M172V/
E427K		G432SG54AG54R M220K M220RWild-Type (n = 7) b G51AM217IY491HATCC
204304 *		Wild-Type (n = 2) b
Triazole fungicides
 Prothioconazole>32 (32->32)>32 (4->32)>32>32>32>3232>32>3232>32>32 (>32)>32>32>32>32>32
 Mefentrifluconazole>32 (16->32)>32 (32->32)>32>32>32>32>32>32>32>32>328 (1->32)>32>32>32>32>32
 Paclobutrazole32 (16–32)16 (16)>32>32>32>323232>3232>328 (1–32)8323288; 16
 Epoxiconazole16 (8–16)8 (4–16)>32>32>32>32>321616>32162 (1–4)16>32816 (8–16)8; 16
 Propiconazole8 (4–16)8 (4–8)>32>32>32>32>3216816162 (1–8)16>32816 (16–32)16; 32
 Tebuconazole4 (4–8)4 (2–4)32>32>323232432882 (1–8)163288 (4–8)4; 8
 Difenoconazole4 (2–16)2 (1–4)>32>32>32321642880.5 (0.125–2)4428 (4–16)8;16
 Metconazole0.25 (0.25–0.5)0.25 (0.25)2216110.580.50.50.5 (0.125–1)1222 (2–4)2; 4
 Prothioconazole-desthio0.125 (0.06–0.125)0.06 (0.06–0.125)0.1250.2510.1250.1250.12540.1250.1250.5 (0.125–0.5)0.250.50.50.50.5
Imidazole fungicides
 Prochloraz0.50.25 (0.25–0.5)2232120.580.520.5 (0.25–4)24411
 Imazalil0.25 (0.25–0.5)0.25 (0.125–0.5)483224120.50.50.5 (0.125–1)2212 (1–2)1; 2
Medical triazoles
 Itraconazole 0.25 (0.25–0.5)0.25 (0.125–0.5)>32>320.5>32>32>32>32>32>320.25 (0.06–0.5)>32>3210.125 (0.125–0.25)0.125; 0.25
 Posaconazole 0.125 (0.06–0.125)0.125 (0.03–0.125)210.5114>3220.50.125 (0.06–0.25)0.50.50.50.125 (0.125–0.25)0.125
 Isavuconazole 1 (1–2)1 (0.5–1)816>3248116221 (0.25–4)2841 (1–2)1; 2
 Voriconazole 1 (0.5–2)1 (0.25–1)88>322418210.5 (0.25–1)24411
Fungicide metabolites
 1,2,4-Triazole>16 (>16)>16 (>16)>16>16>16>16>16>16>16>16>16>16 (>16)>16>16>16>16 (>16)>16
 1,2,3-Triazole>16 (>16)>16 (>16)>16>16>16>16>16>16>16>16>16>16 (>16)>16>16>16>16 (>16)>16
 Triazole alanine>16 (>16)>16 (>16)>16>16>16>16>16>16>16>16>16>16 (>16)>16>16>16>16 (>16)>16
 Triazole acetate >16 (>16)>16 (>16)>16>16>16>16>16>16>16>16>16>16 (>16)>16>16>16>16 (>16)>16
 Triazole sulfonamide>16 (>16)>16 (>16)>16>16>16>16>16>16>16>16>16>16 (>16)>16>16>16>16 (>16)>16
Non-azole fungicides
 Bixafen>32 (>32)>32 (>32)>32>32>32242>328>32>32 (>32)>32>32>32>32 (>32)>32
 Boscalid>32 (>32)>32 (>32)>32>32>32222>32>32>32>32 (>32)>32>32>32>32 (>32)>32
 Fluxapyroxad>32 (>32)>32 (>32)>32>32>32212>32>32>32>32 (>32)>32>32>32>32 (>32)>32
 Fluopyram>32 (>32)>32 (>32)>32>32>32416432>32>32>32 (>32)>32>32>32>32 (>32)>32
 Folpet>32 (>32)>32 (>32)>32>32>32321632>3232>32>32 (>32)>3232>32>32 (>32)>32
 Azoxystrobin>32 (>32)>32 (>32)>32>32>328>3232>32>32>322 (0.5–8)>32>3216>32 (>32)>32
* MIC50 (range) of six repetitions; a MIC50 (range) of the MICs for 7 isolates; b MICs for each of the two A. terreus sensu stricto isolates included. The A. terreus cyp51A wild-type isolate with lowest MICs was found to harbour a calmodulin deletion.
Table
Table 2. Relative susceptibility of mutant isolates compared to same species wild-type isolates determined as Log2(mutant MIC50) – Log2(wild-type MIC). Only agents with activity against wildtype isolates are included. Differences of ≥3 Log2 MICs are highlighted in bold, and of ≥4 Log2 MICs are underlined. Negative values represent cases where the mutant isolate is more susceptible than its wild-type counterpart.
Table 2. Relative susceptibility of mutant isolates compared to same species wild-type isolates determined as Log2(mutant MIC50) – Log2(wild-type MIC). Only agents with activity against wildtype isolates are included. Differences of ≥3 Log2 MICs are highlighted in bold, and of ≥4 Log2 MICs are underlined. Negative values represent cases where the mutant isolate is more susceptible than its wild-type counterpart.
A. fumigatusA. terreus
TR34/L98HTR34(3)/L98HTR46/Y121F/T289ATR120/F46Y/M172V/E427KG432SG54AG54RM220KM220RG51AM217IY491H
Triazole fungicides
Mefentrifluconazole000000000333
Paclobutrazole222211212022
Epoxiconazole *333331131352
Propiconazole *333331011352
Tebuconazole *344330311342
Difenoconazole *555431022332
Metconazole336221511122
Prothioconazole-desthio124111611−100
Imidazole fungicides
Prochloraz337231513233
Imazalil 457342311221
Medical triazoles
Itraconazole 881888888882
Posaconazole 432335942222
Isavuconazole 346230411132
Voriconazole336120310233
Strobilurin
Azoxystrobin000−30−1000553
* Compounds previously associated with azole resistance selection potential [14].
Table
Table 3. Comparison of azole degradation times (DT50 (half-life)) in soil as given in EFSA summary reports.
Table 3. Comparison of azole degradation times (DT50 (half-life)) in soil as given in EFSA summary reports.
Azole FungicideDT50 in Soil (20 °C)
(Range in Days)		Source (Link to Specific EFSA Document)
Difenoconazole 53–235https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2011.1967
Prothioconazole1.3–2.8https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2007.106r
Prothioconazole-destio7–34https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2007.106r
Tebuconazole 20–92https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2014.3485
Metconazole84–598https://www.efsa.europa.eu/en/consultations/call/180801
Propiconazole28–131https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2017.4887
Epoxiconazole98–694https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2008.138r
Imazalil41–135https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2010.1526
Mefentrifluconazole104–477https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2018.5379
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Jørgensen, K.M.; Helleberg, M.; Hare, R.K.; Jørgensen, L.N.; Arendrup, M.C. Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance. J. Fungi 2021, 7, 205. https://doi.org/10.3390/jof7030205

AMA Style

Jørgensen KM, Helleberg M, Hare RK, Jørgensen LN, Arendrup MC. Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance. Journal of Fungi. 2021; 7(3):205. https://doi.org/10.3390/jof7030205

Chicago/Turabian Style

Jørgensen, Karin Meinike, Marie Helleberg, Rasmus Krøger Hare, Lise Nistrup Jørgensen, and Maiken Cavling Arendrup. 2021. "Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance" Journal of Fungi 7, no. 3: 205. https://doi.org/10.3390/jof7030205

APA Style

Jørgensen, K. M., Helleberg, M., Hare, R. K., Jørgensen, L. N., & Arendrup, M. C. (2021). Dissection of the Activity of Agricultural Fungicides against Clinical Aspergillus Isolates with and without Environmentally and Medically Induced Azole Resistance. Journal of Fungi, 7(3), 205. https://doi.org/10.3390/jof7030205

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop